article thumbnail

Unlocking the potential of mucoadhesive drug delivery

Drug Discovery World

Ashley Rein , Global Market Manager for Topical Drug Delivery at Lubrizol Life Science Health (LLS Health), explains how by using mucoadhesive drug delivery, developers can bring novel drugs to market and maximise the efficacy of pre-existing APIs. . Consider drug delivery systems early on .

article thumbnail

Maculus Therapeutix welcomes Privity FZ LLE and Prepares Capital Raise for Novel Drug Delivery Platform

Pharma Mirror

Maculus plans to raise USD3 million on a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies. Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, MacuBloc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

XPhyto Announces RT-PCR Test for Point-of-Care COVID-19 Detection

The Pharma Data

The test is planned for commercial launch as a CE-IVD ( in vitro diagnostic) certified product in the European Union in Q1 2021. . VANCOUVER, BC / ACCESSWIRE / October 28, 2020 / XPhyto Therapeutics Corp. “We are currently developing two saliva-based tests to detect SARS-CoV-2 RNA. About XPhyto Therapeutics Corp.

RNA 52
article thumbnail

Changing Faces: biopharma hires from November 2022

pharmaphorum

Oxsonics Therapeutics, which offers an ultrasound-based drug delivery platform, appointed Jérôme Marzinski, a board member at Cimon Medical and former CEO of ophthalmic diagnostic company Visiometrics into its top job. The month of November saw a number of notable hires and personnel moves in biotech and pharma. More CEO shakeups.

Sales 52
article thumbnail

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

Emerging as a new treatment option in rare and orphan disease areas, oligonucleotide therapeutics have matured into a drug class with a broad indication spectrum. Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake.

article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

As the industry moves to reduce the use of animals in research and testing, aptamers also support here, as they are discovered, developed, and manufactured entirely in vitro , removing the need for animals in antibody discovery processes. AT : The major interest we see is in the targeted delivery of therapeutic molecules.

article thumbnail

JS Bio and Etta Biotech Advancing Strategic Partnership

The Pharma Data

It has become the de facto standard equipment for high titer transient protein expression platforms used by many leading Chinese antibody drug pharmaceutical companies and IVD (In Vitro Diagnostics) companies since its launch in Oct. for non-viral cell immunotherapeutic drug development. JS Bio’s parent company.

Protein 52